15-min delayed · Aug 27, 9:30 AM ET · Get real-time quotes →
ANALYST CONSENSUS0 ratings
No Rating
Strong Buy00%
Buy00%
Hold00%
Sell00%
Strong Sell00%
Analyst rating coverage is not available for MDNAF yet.
12-MONTH PRICE TARGET
—
Average analyst target vs $0.32 current
Highest Target—
Average Target—
Lowest Target—
MDNAF analyst recommendation trends
86420
Aug
Sep
Oct
Nov
Strong BuyBuyHoldSellStrong Sell
RATING
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
Buy
1
1
1
1
Hold
0
0
0
0
Sell
0
0
0
0
Strong Sell
0
0
0
0
Total
1
1
1
1
As of Nov, 1 of 1 firms rate MDNAF a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MDNAF EPS & revenue forecast
EPS · NEXT QUARTER
$-0.04
Range $-0.04 – $-0.04 · 2 analysts · +8% YoY
Next period, 2 analysts expect Medicenna Therapeutics Corp to earn $-0.04 a share (range $-0.04 – $-0.04), versus $-0.04 a year earlier. Full-year consensus is $-0.16, growing to $-0.36 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 2 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $1.3M next year.
Top analysts covering Medicenna Therapeutics Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDNAF.
#1
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #243
Buy
$2.50+669.7% to target
Overall win rate
38%
+ Follow
#2
DM
David Martin PhD
Bloom Burton
Buy
$4.00+1131.5% to target
Coverage
—
+ Follow
#3
DP
Dev Prasad
Lucid Capital
Buy
$4.00+1131.5% to target
Coverage
—
+ Follow
MDNAF stock forecast FAQ
Who is the most accurate analyst covering MDNAF?+
Among analysts who currently cover MDNAF, Swayampakula Ramakanth of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #243). Their current call is Buy with a $2.50 target.
What is Medicenna Therapeutics Corp's projected EPS for next quarter?+
The consensus estimate is $-0.04 per share (range $-0.04 – $-0.04) across 2 analysts. Full-year EPS is projected at $-0.16, rising to $-0.36 the following year.
How much revenue is Medicenna Therapeutics Corp expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $1.3M next year.
Have analysts been upgrading or downgrading MDNAF lately?+
As of Nov, 1 of 1 firms rate MDNAF a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDNAF calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
